22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot-Based Methods for Therapeutic Drug Monitoring.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dried blood spot (DBS) analysis has been introduced more and more into clinical practice to facilitate Therapeutic Drug Monitoring (TDM). To assure the quality of bioanalytical methods, the design, development and validation needs to fit the intended use. Current validation requirements, described in guidelines for traditional matrices (blood, plasma, serum), do not cover all necessary aspects of method development, analytical- and clinical validation of DBS assays for TDM. Therefore, this guideline provides parameters required for the validation of quantitative determination of small molecule drugs in DBS using chromatographic methods, and to provide advice on how these can be assessed. In addition, guidance is given on the application of validated methods in a routine context. First, considerations for the method development stage are described covering sample collection procedure, type of filter paper and punch size, sample volume, drying and storage, internal standard incorporation, type of blood used, sample preparation and prevalidation. Second, common parameters regarding analytical validation are described in context of DBS analysis with the addition of DBS-specific parameters, such as volume-, volcano- and hematocrit effects. Third, clinical validation studies are described, including number of clinical samples and patients, comparison of DBS with venous blood, statistical methods and interpretation, spot quality, sampling procedure, duplicates, outliers, automated analysis methods and quality control programs. Lastly, cross-validation is discussed, covering changes made to existing sampling- and analysis methods. This guideline of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology on the development, validation and evaluation of DBS-based methods for the purpose of TDM aims to contribute to high-quality micro sampling methods used in clinical practice.

          Related collections

          Author and article information

          Journal
          Ther Drug Monit
          Therapeutic drug monitoring
          Ovid Technologies (Wolters Kluwer Health)
          1536-3694
          0163-4356
          August 2019
          : 41
          : 4
          Affiliations
          [1 ] Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
          [2 ] Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
          [3 ] PRA Health Sciences, Bioanalytical Laboratory, Assen, the Netherlands.
          [4 ] Professor Emeritus, Dalarna University College, Borlänge, Sweden.
          [5 ] MVZ Labor Dessau GmbH, Dessau-Roßlau, Germany.
          [6 ] Spark Holland BV, Emmen, the Netherlands.
          [7 ] Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.
          [8 ] Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands.
          [9 ] Laboratory of Analytical Toxicology, Institute of Health Sciences, Universidade Feevale, Novo Hamburgo, Brazil.
          [10 ] Department of Chemistry, West Chester University, West Chester, Pennsylvania.
          [11 ] Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, the Netherlands.
          [12 ] Department of Pharmaceutical Analysis, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands.
          [13 ] School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
          [14 ] Westmead Hospital, Sydney, Australia.
          Article
          10.1097/FTD.0000000000000643
          31268966
          f0dd6eab-c156-4567-8ef9-0e6925304815
          History

          Comments

          Comment on this article